Rosa A. van Amerongen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rosa A. van Amerongen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Mirjam H. M. Heemskerk
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Peter van Veelen
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
21 shared publications - Anne K. Wouters
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
20 shared publications - Arnoud H. de Ru
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands
20 shared publications - Dennis F. G. Remst
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
20 shared publications - Dirk M. van der Steen
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
20 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Peptide titrations of T-cell clones selected to recognize peptide-loaded and gene transduced Raji cells. IFN-ƴ production (ng/mL) of T-cell clones cocultured overnight with Raji cells (transduced with HLA-A2, B7 or B35) loaded with titrated peptide concentrations (E:T=1:6). Graphs are separated based on T-cell specificity. The five selected T-cell clones are shown in color. Values represent averaged duplicate values. (E:T: effector:target ratio)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Peptide titrations of T-cell clones selected to recognize peptide-loaded and gene transduced Raji cells. IFN-ƴ production (ng/mL) of T-cell clones cocultured overnight with Raji cells (transduced with HLA-A2, B7 or B35) loaded with titrated peptide concentrations (E:T=1:6). Graphs are separated based on T-cell specificity. The five selected T-cell clones are shown in color. Values represent averaged duplicate values. (E:T: effector:target ratio)
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
IFN-ƴ production (ng/mL) of T cell clones 23.1A6 (KLK4-A2), 40.1.A8 (KLK4-A2), 41.1H9 (KLK4-A2), 36.2.2E3 (KLK3-B35) and 29.1.1C12 (KLK3-B35) after overnight coculture with 25 different EBV-LCLs, expressing all HLA alleles with an allele frequency > 1% present in the Caucasian population (E:T=1:6). Bars represent mean and SD of technical duplicates. (EBV-LCL: Epstein-Barr virus transformed lymphoblastoid cell lines, E:T: effector:target ratio)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
IFN-ƴ production (ng/mL) of T cell clones 23.1A6 (KLK4-A2), 40.1.A8 (KLK4-A2), 41.1H9 (KLK4-A2), 36.2.2E3 (KLK3-B35) and 29.1.1C12 (KLK3-B35) after overnight coculture with 25 different EBV-LCLs, expressing all HLA alleles with an allele frequency > 1% present in the Caucasian population (E:T=1:6). Bars represent mean and SD of technical duplicates. (EBV-LCL: Epstein-Barr virus transformed lymphoblastoid cell lines, E:T: effector:target ratio)
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) KLK2, (B) KLK3 (PSA), (C) KLK4 (D) HOXB13, (E) ACPP (PAP), and (F) MSMB expression in prostate cancer (TCGA data, n=30), healthy prostate (TCGA data, n=30) and across 51 (GTEx data, n=5-20) healthy tissue types, respectively. Red, green, grey and white boxplots represent prostate cancer, healthy prostate, testis and all remaining healthy tissues, respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. The upper black and lower red dashed lines represent the median expression value and the 80 fold lower expression value, respectively. X-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer
Boxplots depicting (A) KLK2, (B) KLK3 (PSA), (C) KLK4 (D) HOXB13, (E) ACPP (PAP), and (F) MSMB expression in prostate cancer (TCGA data, n=30), healthy prostate (TCGA data, n=30) and across 51 (GTEx data, n=5-20) healthy tissue types, respectively. Red, green, grey and white boxplots represent prostate cancer, healthy prostate, testis and all remaining healthy tissues, respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. The upper black and lower red dashed lines represent the median expression value and the 80 fold lower expression value, respectively. X-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)